These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38070405)

  • 21. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: A study of 34 patients.
    Caraballo RH; Pociecha J; Reyes G; Espeche A; Galichio S; Fasulo L; Semprino M
    Epilepsy Behav; 2020 Jul; 108():107074. PubMed ID: 32334364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
    Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
    Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and Tolerability of 12-Month Brivaracetam in the Real World: EXPERIENCE, an International Pooled Analysis of Individual Patient Records.
    Villanueva V; Laloyaux C; D'Souza W; Faught E; Klein P; Reuber M; Rosenow F; Salas-Puig J; Insuga VS; Strzelczyk A; Szaflarski JP; Chinn C; Daniels T; Floricel F; Friesen D; Sendersky V; Besson H; Steinhoff BJ
    CNS Drugs; 2023 Sep; 37(9):819-835. PubMed ID: 37684497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with brivaracetam in a series of 46 children.
    Visa-Reñé N; Raspall-Chaure M; Paredes-Carmona F; Coromina JS; Macaya-Ruiz A
    Epilepsy Behav; 2020 Jun; 107():107067. PubMed ID: 32302941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients.
    Reed RC; Rosenfeld WE; Lippmann SM; Eijkemans RMJC; Kasteleijn-Nolst Trenité DGA
    CNS Drugs; 2020 Oct; 34(10):1075-1086. PubMed ID: 32949370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study.
    Menzler K; Mross PM; Rosenow F; Schubert-Bast S; Willems LM; Zahnert F; Immisch I; Fuest S; von Podewils F; Kunz R; Hirsch M; Mueller T; Marquetand J; Winter Y; Langenbruch L; Cicanic M; Beyenburg S; Strzelczyk A; Knake S
    BMJ Open; 2019 Nov; 9(11):e030746. PubMed ID: 31690606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brivaracetam as add-on treatment in focal epilepsy: A real-world time-based analysis.
    Lattanzi S; De Maria G; Rosati E; Didato G; Chiesa V; Ranzato F; Canafoglia L; Cesnik E; Anzellotti F; Meletti S; Pauletto G; Nilo A; Bartolini E; Marino D; Tartara E; Luisi C; Bonanni P; Marrelli A; Stokelj D; Dainese F
    Epilepsia; 2021 Jan; 62(1):e1-e6. PubMed ID: 33314118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy.
    Svendsen T; Brodtkorb E; Linge HL; Burns ML; Johannessen SI; Nakken KO; Lossius MI; Landmark CJ
    Epilepsy Res; 2022 Jul; 183():106946. PubMed ID: 35609355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
    Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
    Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
    Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
    Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial.
    Lagae L; Klotz KA; Fogarasi A; Floricel F; Reichel C; Elshoff JP; Fleyshman S; Kang H
    Epilepsia; 2023 Nov; 64(11):2934-2946. PubMed ID: 37597326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, Retention, and Tolerability of Brivaracetam in Patients With Epileptic Encephalopathies: A Multicenter Cohort Study From Germany.
    Willems LM; Bertsche A; Bösebeck F; Hornemann F; Immisch I; Klein KM; Knake S; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; von Podewils F; Reif PS; Steinhoff BJ; Steinig I; Rosenow F; Schubert-Bast S; Strzelczyk A
    Front Neurol; 2018; 9():569. PubMed ID: 30083127
    [No Abstract]   [Full Text] [Related]  

  • 33. Brivaracetam efficacy and safety in focal epilepsy.
    Makke Y; Abou-Khalil B
    Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
    [No Abstract]   [Full Text] [Related]  

  • 34. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities.
    Theochari E; Cock H; Lozsadi D; Galtrey C; Arevalo J; Mula M
    Epilepsy Behav; 2019 Jan; 90():129-131. PubMed ID: 30530134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
    Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
    Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and tolerability of adjunctive brivaracetam for the treatment of adult epilepsy: An Australian multi-center retrospective real-world observational cohort study.
    Halliday AJ; Vogrin S; Ignatiadis S; Gillinder L; Jones D; Kiley M; Kwan P; Seneviratne U; Somerville E; Whitham E;
    Epilepsy Behav; 2023 Aug; 145():109287. PubMed ID: 37336131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
    Gillis RME; Wammes-van der Heijden EA; Schelhaas HJ; Tan IY; Festen DAM; Majoie MHJM
    Acta Neurol Belg; 2021 Jun; 121(3):677-684. PubMed ID: 32157673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
    Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
    Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential role of brivaracetam in pediatric epilepsy.
    Verrotti A; Grasso EA; Cacciatore M; Matricardi S; Striano P
    Acta Neurol Scand; 2021 Jan; 143(1):19-26. PubMed ID: 32966640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brivaracetam as add-on treatment in patients with post-stroke epilepsy: real-world data from the BRIVAracetam add-on First Italian netwoRk Study (BRIVAFIRST).
    Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Irelli EC; Chiesa V; Dainese F; De Maria G; Didato G; Gennaro GD; Falcicchio G; Fanella M; Ferlazzo E; Gangitano M; La Neve A; Mecarelli O; Montalenti E; Morano A; Piazza F; Pizzanelli C; Pulitano P; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
    Seizure; 2022 Apr; 97():37-42. PubMed ID: 35320736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.